Is XORTX Therapeutics Inc. (XRTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 75.8% / 30% | 0.5% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 75.8% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.9% / 33% | 60.4% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 75.8% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.9% / 33% | 60.4% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -98.0% | |
| Return on Assets (ROA) | -46.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$3M |
| Total Debt | $37,287 |
| Debt-to-Equity | 1.8 |
| Current Ratio | 2.1 |
| Total Assets | $3M |
Price & Trading
| Last Close | $0.35 |
| 50-Day MA | $0.45 |
| 200-Day MA | $0.68 |
| Avg Volume | 146K |
| Beta | 0.1 |
|
52-Week Range
$0.34
| |
About XORTX Therapeutics Inc. (XRTX)
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is XORTX Therapeutics Inc. (XRTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), XORTX Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is XORTX Therapeutics Inc.'s debt ratio?
XORTX Therapeutics Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
What are XORTX Therapeutics Inc.'s key financial metrics?
XORTX Therapeutics Inc. has a market capitalization of $3M. Return on equity stands at -98.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.